Pelthos Therapeutics Inc.
PTHS
Positions held
Your positionsPTHS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $78.48M | Enterprise value | $127.40M | Trailing P/E | — | Forward P/E | -3.61 |
| PEG | — | Price / book | -50.74 | Beta | 3.11 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 75.6% | Operating margin | -101.4% |
| Profit margin | -2.0% | ROE | — | ROA | -50.0% | Debt / equity | — |
| Current ratio | 1.98 | Free cash flow | -$36.57M | Analyst recommendation | strong_buy | Mean target | $53.14 |
| 52w high | $37.50 | 52w low | $18.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $9.4M | $7.4M | $0.0M |
| Op margin | -111.0% | -120.0% | -127.8% | -207.4% | — |
| Net income | -$23.4M | -$25.1M | -$21.7M | -$16.2M | -$3.4M |
| Gross margin | 17.8% | 51.3% | 53.2% | 32.8% | — |
| Gross profit | $2.8M | $5.6M | $5.0M | $2.4M | $0.0M |
| Operating income | -$17.3M | -$13.1M | -$12.0M | -$15.4M | -$3.2M |
- Revenue +43% vs prior quarter ($16M vs $11M).
- Gross margin 17.8% (was 51.3% prior quarter).
- Operating margin expanded to -111%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $16.8M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -193.1% | — | — | — | — |
| Net income | -$43.3M | -$8.0M | -$7.4M | -$2.5M | — |
| Gross margin | 44.2% | — | — | — | — |
| Gross profit | $7.4M | $0.0M | — | — | — |
| Operating income | -$32.4M | -$7.6M | -$6.9M | -$2.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
2026-08-20 · Pelthos (PTHS) Q2 2026 Earnings Call Transcript
2026-08-14 · Pelthos Therapeutics Q2 Earnings Call Highlights
2026-08-13 · Pelthos Therapeutics Inc (PTHS) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as ...
2026-08-13 · Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 · Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-12 · Earnings To Watch: Pelthos Therapeutics Inc (PTHS) Reports Q2 2026 Result
2026-08-06 · This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone
2026-08-03 · Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
2026-07-24 · Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Price (daily)
Full chart · RSI · MACD · patterns